Xeris Biopharma (XERS) reported $92.1 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 28.7%. EPS of $0 for the same period compares to -$0.01 a year ago.
The reported revenue represents a surprise of +1.51% over the Zacks Consensus Estimate of $90.73 million. With the consensus EPS estimate being $0.02, the EPS surprise was -100%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Xeris Biopharma performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Revenue- Gvoke: $22.55 million versus $22.13 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -3.9% change. Product Revenue- Recorlev: $56.78 million versus the three-analyst average estimate of $55.97 million. The reported number represents a year-over-year change of +394.4%. Revenue- Royalty, contract and other: $1.1 million versus the three-analyst average estimate of $1.4 million. The reported number represents a year-over-year change of -71.4%. Revenue- Product revenue, net: $91 million versus the three-analyst average estimate of $89.34 million. The reported number represents a year-over-year change of +34.4%. Product Revenue- Keveyis: $11.68 million versus $11.25 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -62.9% change.View all Key Company Metrics for Xeris Biopharma here>>>
Shares of Xeris Biopharma have returned -6.5% over the past month versus the Zacks S&P 500 composite's +3.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Xeris Biopharma Holdings, Inc. (XERS): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).